Article

Macusight's lead product has positive phase 1 results

Union City, CA-MacuSight's lead product candidate, sirolimus, for patients with chronic, clinically significant diabetic macular edemahas shown positive initial results in its phase 1 study.

Union City, CA-MacuSight's lead product candidate, sirolimus, for patients with chronic, clinically significant diabetic macular edemahas shown positive initial results in its phase 1 study.

These findings were presented at the 40th annual meeting of the Retina Society by Mark Blumenkranz, MD, chairmen of MacuSight's scientific advisory board and professor and chairman of the department of ophthalmology, Stanford University School of Medicine.

The study was randomized, open-label and investigators analyzed the safety, tolerability, and biological activity of sirolimus when delivered by either subconjunctival or intravitreal injection.

Subconjunctival injections, which are less invasive and more convenient, were used instead of the intravitreal injections, which sometimes caused patient discomfort and a risk of serious infection in some patients.

Patients who received the subconjunctival injection had mean improvements in visual acuity of 8.5 and 7.4 letters over baseline, using the standard ETDRS eye chart. Foveal thickness also decreased.

There was no sign of increased IOP or inflammatory response, and MacuSight intends to complete its collection and analysis of all data from this trial and present final findings next year.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.